WHO ICTRP trial
MB-CART19.1 in refractory SLE
EUCTR2022-003137-19-DE · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2022-003137-19-DE |
|---|---|
| Public title | MB-CART19.1 in refractory SLE |
| Scientific title | An open-label phase I/IIa, multicenter, interventional single-arm trial of MB-CART19.1 in patients with refractory SLE - MB-CART19.1 in refractory SLE |
| Primary sponsor | Miltenyi Biomedicine GmbH |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): yes Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Germany |
| Conditions | Adult patients with refractory active systemic lupus erythematosus (SLE) with organ involvement MedDRA version: 21.1 Level: PT Classification code 10042945 Term: Systemic lupus erythematosus System Organ Class: 10028395 - Musculoskeletal… |
| Interventions | Product Name: MB-CART19.1 Product Code: MB-CART19.1 Pharmaceutical Form: Dispersion for infusion INN or Proposed INN: not available Current Sponsor code: MB-CART19.1 Other descriptive name: T cells transduced with chimeric antigen receptor… |
| Registration date | Dec 23, 2022 |
| Target size | 30 |
| Secondary IDs | M-2022-398 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: